| 前收盘价格 | 55.05 |
| 收盘价格 | 54.93 |
| 成交量 | 1,190,930 |
| 平均成交量 (3个月) | 1,180,879 |
| 市值 | 4,125,264,640 |
| 价格/销量 (P/S) | 67.34 |
| 股市价格/股市净资产 (P/B) | 6.88 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 - 4 Aug 2025 |
| 营业利益率 (TTM) | -285.94% |
| 稀释每股收益 (EPS TTM) | -4.16 |
| 季度收入增长率 (YOY) | 235.80% |
| 总债务/股东权益 (D/E MRQ) | 1.65% |
| 流动比率 (MRQ) | 5.86 |
| 营业现金流 (OCF TTM) | -237.91 M |
| 杠杆自由现金流 (LFCF TTM) | -112.40 M |
| 资产报酬率 (ROA TTM) | -30.61% |
| 股东权益报酬率 (ROE TTM) | -58.66% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Merus N.V. | 看涨 | 看跌 |
AIStockmoo 评分
1.5
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.50 |
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 1.85% |
| 机构持股比例 | 106.93% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 110.00 (BMO Capital, 98.59%) | 购买 |
| 中 | 99.00 (78.73%) | |
| 低 | 88.00 (Needham, 58.87%) | 购买 |
| 平均值 | 99.00 (78.73%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 49.42 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BMO Capital | 23 May 2025 | 110.00 (98.59%) | 购买 | 55.14 |
| Needham | 23 May 2025 | 88.00 (58.87%) | 购买 | 55.14 |
| 19 May 2025 | 75.00 (35.40%) | 购买 | 41.36 | |
| Wells Fargo | 08 May 2025 | 89.00 (60.68%) | 购买 | 42.77 |
| Guggenheim | 28 Mar 2025 | 109.00 (96.79%) | 购买 | 44.61 |
| 18 Mar 2025 | 109.00 (96.79%) | 购买 | 46.39 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合